From a clinical point of view, this report suggests that blockage of the ‘axon guidance' family and, more specifically, the SLIT2/ROBO pathway and its following signaling (as β-catenin/N-cadherin), may be a therapeutic approach to reduce PANR as well as consequent pathophysiologic impacts on PDA development and patient's fate (in the form of tumor recurrence and neuropathic pain). The gene discussed is CDH2; the disease is Patent ductus arteriosus.